Market Overview

The Global Breast Cancer Screening Test Market was valued at USD 3,253.5 million in 2023 and is expected to reach USD 6,724.5 million by 2031 while growing at a CAGR of 9.5% during the forecast period (2024-2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Market Dynamics

This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global breast cancer screening test market growth.  A breast cancer screening test aims to detect breast cancer in its early stages, typically before symptoms develop, through medical examination or procedures. The goal is to identify small tumors or abnormalities in breast tissue, enhancing the chances of successful treatment.

The increasing incidence of breast cancer, coupled with technological advancements in breast imaging techniques like digital mammography, breast MRI, and tomosynthesis (3D mammography), drive the breast cancer screening test market. However, cost and affordability issues, along with concerns about overdiagnosis and false positives, restrain the growth of the market.

Furthermore, the global breast cancer screening test industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.

Segmentation – By Test Analysis

The Global Breast Cancer Screening Test Market is segmented among Genomic Tests, and Imaging Tests, based on Test. In 2023, Imaging Test accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Global Breast Cancer Screening Test Market: Regional Analysis

Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Competitive Landscape

Some of the key players operating in the market are F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Koninklijke Philips N.V., Carestream Health, GE Healthcare, Fujifilm Holdings Corporation, NanoString Technologies, Inc., Siemens Healthineers, Hologic Inc., and Quest Diagnostics Incorporated.

Table of Contents:

1. Research Methodology and Market Scope

• Research Methodology

• Market Scope

2. Executive Summary

3. Global Breast Cancer Screening Test Market Dynamics

• Drivers

• Restraints

• Opportunity

4. Global Breast Cancer Screening Test Industry Analysis

• PEST Analysis

• Porter's Five Force Analysis

• Recent Deals Analysis

5. Global Breast Cancer Screening Test Market Segmentation, By Test

• Global Breast Cancer Screening Test Market Share Analysis, By Test

• Global Breast Cancer Screening Test Market Growth Analysis, By Test

• Global Breast Cancer Screening Test Market Trends, By Test

o Genomic Tests

o Imaging Test

Ø Mammograms

Ø Ultrasound

Ø MRI

Ø Tomography

Ø Other Imaging Tests

6. Global Breast Cancer Screening Test Market Segmentation, By Region

• Global Breast Cancer Screening Test Market Share Analysis, By Region

• Global Breast Cancer Screening Test Market Growth Analysis, By Region

• Global Breast Cancer Screening Test Market Trends, By Region

o North America

o Europe

o Asia Pacific

o Latin America

o Middle East

o Africa

7. Competitive Landscape

• F. Hoffmann-La Roche Ltd*

o Company Overview

o Financial Performance

o Key Development/Strategies

o SWOT Analysis

• Myriad Genetics, Inc.

• Koninklijke Philips N.V.

• Carestream Health

• GE Healthcare

• Fujifilm Holdings Corporation

• NanoString Technologies, Inc.

• Siemens Healthineers

• Hologic Inc.

• Quest Diagnostics Incorporated

 *Similar analysis will be provided for each company listed above.